ISL
FRTX

Ingalls & Snyder LLC’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Ingalls & Snyder LLC’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4
Closed -$14K – 391
2014
Q1 		$14K Sell
4
-54
-93% -$241K ﹤0.01% 368
2013
Q4 		$216K Sell
58
-10
-15% -$37.9K 0.01% 321
2013
Q3 		$269K Sell
68
-53
-44% -$398K 0.02% 290
2013
Q2 		$1.2M Buy
+121
New +$1.34M 0.08% 164

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return

Ingalls & Snyder LLC's FRTX Position: Q2 2014 in Review

Ingalls & Snyder LLC sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2014, closing a stake of 4 shares — an estimated $14K sold.

Ingalls & Snyder LLC first reported a position in FRTX in Q2 2013 and held it in 4 quarters. The position peaked at $1.2M in Q2 2013. 70 funds tracked by Wall St. Rank hold FRTX as of Q2 2014.

  • Ingalls & Snyder LLC reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 4 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2014, an estimated $14K.
  • Ingalls & Snyder LLC first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 4 quarters.
  • Ingalls & Snyder LLC's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $1.2M in Q2 2013.
  • 70 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2014.

Based on Ingalls & Snyder LLC's 13F filing for Q2 2014, filed 30 Jul 2014.